These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 27704468)

  • 41. High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.
    Raphael BA; Shin DB; Suchin KR; Morrissey KA; Vittorio CC; Kim EJ; Gardner JM; Evans KG; Introcaso CE; Samimi SS; Gelfand JM; Rook AH
    Arch Dermatol; 2011 Dec; 147(12):1410-5. PubMed ID: 21844430
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cutaneous T-cell lymphoma.
    Gemmill R
    Semin Oncol Nurs; 2006 May; 22(2):90-6. PubMed ID: 16720231
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
    Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
    J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TOX expression in different subtypes of cutaneous lymphoma.
    Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).
    Olsen EA; Rook AH; Zic J; Kim Y; Porcu P; Querfeld C; Wood G; Demierre MF; Pittelkow M; Wilson LD; Pinter-Brown L; Advani R; Parker S; Kim EJ; Junkins-Hopkins JM; Foss F; Cacchio P; Duvic M
    J Am Acad Dermatol; 2011 Feb; 64(2):352-404. PubMed ID: 21145619
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current treatment of Cutaneous T-Cell Lymphoma.
    Duvic M
    Dermatol Online J; 2001 Feb; 7(1):3. PubMed ID: 11328624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
    Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
    Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
    Martinez-Escala ME; Kuzel TM; Kaplan JB; Petrich A; Nardone B; Rosen ST; Guitart J
    JAMA Oncol; 2016 Jun; 2(6):790-3. PubMed ID: 27054291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic and prognostic importance of T-cell receptor gene analysis in patients with Sézary syndrome.
    Fraser-Andrews EA; Russell-Jones R; Woolford AJ; Wolstencroft RA; Dean AJ; Whittaker SJ
    Cancer; 2001 Oct; 92(7):1745-52. PubMed ID: 11745245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy.
    Fujii K; Karpova MB; Asagoe K; Georgiev O; Dummer R; Urosevic-Maiwald M
    Leukemia; 2015 Oct; 29(10):2024-32. PubMed ID: 25915825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.
    Moriarty B; Whittaker S
    Expert Rev Hematol; 2015 Apr; 8(2):159-71. PubMed ID: 25495961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myocosis fungoides--an update on a non-mycotic disease.
    Makdisi J; Friedman A
    J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extracutaneous transformation into a high-grade lymphoma: a potential pitfall in the management of patients with Sézary syndrome.
    Michaelis S; Kazakov DV; Burg G; Dummer R; Kempf W
    Int J Dermatol; 2006 Mar; 45(3):277-9. PubMed ID: 16533228
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome.
    Moerman-Herzog A; Mehdi SJ; Wong HK
    Cells; 2020 Aug; 9(9):. PubMed ID: 32872487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Histoclinical and immunohistochemical diagnosis of cutaneous lymphomas].
    Maryniak RK; Jankowska-Konsur A
    Pol J Pathol; 2011 Dec; 62(4 Suppl 3):s1-23. PubMed ID: 22693733
    [No Abstract]   [Full Text] [Related]  

  • 56. Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
    Jarrousse V; Quereux G; Marques-Briand S; Knol AC; Khammari A; Dreno B
    Eur J Dermatol; 2006; 16(6):636-41. PubMed ID: 17229603
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cutaneous T-cell lymphoma: CT in evaluation and staging.
    Bass JC; Korobkin MT; Cooper KD; Kane NM; Platt JF
    Radiology; 1993 Jan; 186(1):273-8. PubMed ID: 8416579
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma.
    Kiessling MK; Klemke CD; Kaminski MM; Galani IE; Krammer PH; Gülow K
    Cancer Res; 2009 Mar; 69(6):2365-74. PubMed ID: 19258503
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
    Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
    Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.